SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001136261-22-000174
Filing Date
2022-04-11
Accepted
2022-04-11 08:03:49
Documents
15
Period of Report
2022-04-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 28194
2 AMENDMENT NO. 5 TO ASSET PURCHASE AGREEMENT, DATED APRIL 8, 2022, BY AND BETWEEN exh10-1.htm EX-10.1 15459
3 PRESS RELEASE, DATED APRIL 11, 2022. exh99-1.htm EX-99.1 12027
4 LOGO image4190.jpg GRAPHIC 3218
  Complete submission text file 0001136261-22-000174.txt   245156

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE seel-20220408.xsd EX-101.SCH 3033
6 XBRL LABEL FILE seel-20220408_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE seel-20220408_pre.xml EX-101.PRE 22595
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3596
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 22818516
SIC: 2834 Pharmaceutical Preparations